RxDoctor Payments DataLook up a doctor →

Christine Codding, MD

Rheumatology · Oklahoma City, OKNPI 1811968399

Payments from drug & device makers

$2,803,825in general payments, 2019–2025

Across 1,063 payments — averaging $2637.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1M
  • Eli Lilly$470K
  • Novartis$352K
  • GSK$269K
  • Gilead$159K
  • Amgen$149K
  • plus $373K from 19 others
$149,966in research payments, 2019–2025

Across 22 payments — averaging $6816.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$149K
  • Eli Lilly$704

What the payments were for

  • Food & beverage$7,56898%
  • Education$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,803,825 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.

See all rheumatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,423,733
Medicare patients
251
Services billed
81,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib51$327,866
Humira PenAdalimumab33$221,272
Humira(Cf) PenAdalimumab25$170,581
Enbrel SureclickEtanercept20$147,257
HumiraAdalimumab22$143,056
Humira(Cf)Adalimumab13$84,530
Orencia ClickjectAbatacept11$84,289
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen183$5,097
Hydroxychloroquine Sulfate143$3,653
Celecoxib172$3,424
MethotrexateMethotrexate Sodium165$3,148
Febuxostat23$3,104
Cevimeline Hcl20$2,603
Pregabalin85$1,415
Cyclobenzaprine Hcl117$1,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira, Humira(Cf)$1,031,852$555,45286 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 rheumatology providers in Oklahoma.

Other rheumatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →